Shares of Amyris Inc (NASDAQ:AMRS) saw strong trading volume on Tuesday . 999,875 shares were traded during trading, an increase of 181% from the previous session’s volume of 356,429 shares.The stock last traded at $4.75 and had previously closed at $4.22.

A number of equities research analysts have issued reports on the stock. HC Wainwright set a $15.00 target price on shares of Amyris and gave the company a “buy” rating in a report on Wednesday, November 29th. Cowen reissued a “hold” rating and set a $4.00 target price on shares of Amyris in a report on Wednesday, November 29th. ValuEngine cut shares of Amyris from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, Zacks Investment Research raised shares of Amyris from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Amyris has a consensus rating of “Hold” and a consensus target price of $20.69.

The company has a debt-to-equity ratio of -0.78, a quick ratio of 0.82 and a current ratio of 0.92. The company has a market capitalization of $231.95, a price-to-earnings ratio of -0.87 and a beta of 0.16.

Amyris (NASDAQ:AMRS) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The business had revenue of $24.20 million for the quarter, compared to analyst estimates of $36.30 million. Amyris’s revenue for the quarter was down 8.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.07) earnings per share. equities research analysts expect that Amyris Inc will post -3.32 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. Tanaka Capital Management Inc. increased its holdings in shares of Amyris by 72.0% in the third quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock worth $1,691,000 after purchasing an additional 221,295 shares during the period. KBC Group NV increased its holdings in shares of Amyris by 228.4% in the third quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 41,834 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Amyris by 16.3% in the second quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 4,603 shares during the period. Finally, Carl Domino Inc bought a new position in shares of Amyris in the third quarter worth $182,000. 22.84% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This story was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/amyris-amrs-sees-strong-trading-volume/1802935.html.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.